132 related articles for article (PubMed ID: 27792410)
1. Regulation of expression of the p21
Mantsou A; Koutsogiannouli E; Haitoglou C; Papavassiliou AG; Papanikolaou NA
Biochem Cell Biol; 2016 Dec; 94(6):560-568. PubMed ID: 27792410
[TBL] [Abstract][Full Text] [Related]
2. The kinetics of p53-binding and histone acetylation at target promoters do not strictly correlate with gene expression after UV damage.
Magrini R; Russo D; Fronza G; Inga A; Menichini P
J Cell Biochem; 2007 Apr; 100(5):1276-87. PubMed ID: 17063487
[TBL] [Abstract][Full Text] [Related]
3. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
4. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest.
Giono LE; Manfredi JJ
Mol Cell Biol; 2007 Jun; 27(11):4166-78. PubMed ID: 17371838
[TBL] [Abstract][Full Text] [Related]
5. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
[TBL] [Abstract][Full Text] [Related]
6. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).
Zhao Y; Lu S; Wu L; Chai G; Wang H; Chen Y; Sun J; Yu Y; Zhou W; Zheng Q; Wu M; Otterson GA; Zhu WG
Mol Cell Biol; 2006 Apr; 26(7):2782-90. PubMed ID: 16537920
[TBL] [Abstract][Full Text] [Related]
7. Increased Δ133p53 mRNA in lung carcinoma corresponds with reduction of p21 expression.
Fragou A; Tzimagiorgis G; Karageorgopoulos C; Barbetakis N; Lazopoulos A; Papaioannou M; Haitoglou C; Kouidou S
Mol Med Rep; 2017 Apr; 15(4):1455-1460. PubMed ID: 28260096
[TBL] [Abstract][Full Text] [Related]
8. A novel p53 mutant retained functional activity in lung carcinomas.
Ko JL; Chiao MC; Chang SL; Lin P; Lin JC; Sheu GT; Lee H
DNA Repair (Amst); 2002 Sep; 1(9):755-62. PubMed ID: 12509279
[TBL] [Abstract][Full Text] [Related]
9. Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53.
Riscal R; Schrepfer E; Arena G; Cissé MY; Bellvert F; Heuillet M; Rambow F; Bonneil E; Sabourdy F; Vincent C; Ait-Arsa I; Levade T; Thibaut P; Marine JC; Portais JC; Sarry JE; Le Cam L; Linares LK
Mol Cell; 2016 Jun; 62(6):890-902. PubMed ID: 27264869
[TBL] [Abstract][Full Text] [Related]
10. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
[TBL] [Abstract][Full Text] [Related]
11. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
12. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
Fischer M; Quaas M; Nickel A; Engeland K
Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
[TBL] [Abstract][Full Text] [Related]
13. Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.
Kaku S; Iwahashi Y; Kuraishi A; Albor A; Yamagishi T; Nakaike S; Kulesz-Martin M
Nucleic Acids Res; 2001 May; 29(9):1989-93. PubMed ID: 11328884
[TBL] [Abstract][Full Text] [Related]
14. Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types.
Moussa RS; Kovacevic Z; Richardson DR
Oncotarget; 2015 Oct; 6(30):29694-711. PubMed ID: 26335183
[TBL] [Abstract][Full Text] [Related]
15. Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21WAF1/CIP1 in response to the novel anticancer agent, aminoflavone (NSC 686,288).
Meng LH; Kohn KW; Pommier Y
Oncogene; 2007 Jul; 26(33):4806-16. PubMed ID: 17297446
[TBL] [Abstract][Full Text] [Related]
16. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription.
White DE; Talbott KE; Arva NC; Bargonetti J
Cancer Res; 2006 Apr; 66(7):3463-70. PubMed ID: 16585169
[TBL] [Abstract][Full Text] [Related]
17. HBP1-mediated Regulation of p21 Protein through the Mdm2/p53 and TCF4/EZH2 Pathways and Its Impact on Cell Senescence and Tumorigenesis.
Chen Y; Pan K; Wang P; Cao Z; Wang W; Wang S; Hu N; Xue J; Li H; Jiang W; Li G; Zhang X
J Biol Chem; 2016 Jun; 291(24):12688-12705. PubMed ID: 27129219
[TBL] [Abstract][Full Text] [Related]
18. [Expression and clinical significance of P53 pathway-associated proteins in pancreatic carcinoma].
Yu GZ; Zhu MH; Chen Y; Ni CR; Li FM
Ai Zheng; 2005 Nov; 24(11):1398-403. PubMed ID: 16552971
[TBL] [Abstract][Full Text] [Related]
19. FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53.
Ochocka AM; Kampanis P; Nicol S; Allende-Vega N; Cox M; Marcar L; Milne D; Fuller-Pace F; Meek D
FEBS Lett; 2009 Feb; 583(4):621-6. PubMed ID: 19166840
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles.
Yu H; Zou Y; Jiang L; Yin Q; He X; Chen L; Zhang Z; Gu W; Li Y
Biomaterials; 2013 Apr; 34(11):2738-47. PubMed ID: 23352573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
